Clinical Trials
6 trialsNCT04529044 2026-06-05
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Recruiting
NCT04954820 2026-06-04
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Recruiting
NCT06607692 2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT05773274 2026-06-03
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05691465 2026-05-27
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04086485 2026-05-22
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting